A growing sector with scientific tradition
Vienna can look back on an excellent scientific tradition in the field of medical research. Semmelweis, Billroth and Landsteiner are part of this history. The outstanding reputation of the Vienna Medical Schools of the past is carried on today – in academia and on the business side. Vienna’s life sciences community has experienced significant growth for many years. In 2017, a total of 554 companies, research institutions and further core organizations were active in the life science sector in Vienna, having a combined workforce of 37,595 people.
Vienna’s outstanding geographical position and its ranking as offering the best quality of life in the world, make the city an ideal place for marketing products across Europe. All pharmaceutical and medical device companies ranked in the top five worldwide by annual sales have a presence in Vienna. In addition to the international companies, a dynamic start-up scene has been developing since the 1990s. 481 biotechnology, pharmaceutical and medical device companies produce or develop products and processes in these fields in Vienna or are active as suppliers, service or sales companies. These enterprises employed 22,930 people and generated 12.2 billion euros in sales in 2017. Thereof, 177 companies (37%) carry out research or develop and produce innovative products.
Every day we strive to provide safe and efficacious treatments for our patients around the world. By extension of our basic fractionation we’ll be able to double our plasma throughput within the next years. Vienna with its central location, the excellent educational opportunities and its good infrastructure offers best conditions for generating additional jobs to meet the growing demand for our life-saving products in the future.
General Manager at Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.
Besides the strong biotech departments of large companies, Vienna is proud of being home to 78 younger dedicated biotechnology companies. 59 of them focus on health issues: Infectious diseases, neoplasms (cancer) and diseases of the respiratory system are center stage. However, also business areas going beyond medical issues have emerged in Vienna’s biotech community.
Additional 46 dedicated medical device companies are located in Vienna. These have succeeded in establishing particular strengths in the areas of software for medicine, telemedicine and e-health, electromechanical medical devices, assistive products for persons with disabilities and single use devices.
The quality of our home base in Vienna combined with the broad support for research and development in the biotech industry are excellent and inspiring. The close cooperation of industry and academia, plus the generous grants from government bodies, have enabled and provided substantial support for our efforts to develop new treatment options to devastating diseases. Our proprietary master checkpoint blockade mechanism was discovered in Vienna – thanks to the availability of qualified staff, partners and experienced service providers.
CEO APEIRON Biologics AG
Vienna is clearly in first place in Austria when it comes to education and research in the field of life sciences. Five universities, two universities of applied sciences and eleven non-university research institutes employ 12,620 members of staff, which is 60% of all academic employees in this field in Austria. With roughly 34,700 students in the area of life sciences, Vienna educates more young scientists than the rest of Austria. In 2017, 3,725 students graduated with a bachelor’s, master’s or doctoral degree in Vienna, establishing the next generation of researchers. A multitude of publications (4,602 in 2017) in international journals is evidence of the excellent research work in Vienna. Grants provided by the European Research Council became another indicator for quality: At calls issued until the end of 2017, Vienna based researchers succeeded in attracting 84 ERC grants in the life sciences. This represents 72% of all ERC grants in Austria in this sector.
Vienna is Austria’s most important node for high-end medicine. Health professionals at some 25 hospitals not only serve Vienna’s 1.9 million inhabitants, but the whole Vienna region providing home to more than 3.8 million people. Experienced partners for clinical research push back the frontiers of knowledge to the benefit of patients. Commercial partners are welcome to join in. Conduct your clinical trials in Vienna!
With its unique position in the heart of Europe, Vienna is an important and respected hub for the global pharmaceutical and biotech industry. As a gateway between Eastern and Western Europe, it benefits from a well-developed infrastructure and highly qualified professionals. Furthermore, Vienna’s life science community has also experienced a significant growth in recent years.
CEO ABF / Global EVP GBA Group Pharma